Press Releases Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Real-time Estimate Cboe BZX Other stock markets 03:53:40 2024-05-21 pm EDT			5-day change	1st Jan Change
14.72 ^USD	-7.83%		-11.85%	+0.34%

May. 20	BrightSpring Health Services Says Onco360 Selected as Pharmacy Partner for Ojemda	MT
May. 07	HC Wainwright Adjusts Price Target on Day One Biopharmaceuticals to $40 From $50, Maintains Buy Rating	MT

Press Releases

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Day One Reports First Quarter 2024 Financial Results and Corporate Progress	May. 06	GL
Day One Biopharmaceuticals : Corporate Presentation - April 2024	Apr. 24	PU
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	Apr. 23	GL
Day One’s OJEMDA™ (tovorafenib) Receives US FDA Accelerated Approval for Relapsed or Refractory BRAF-altered Pediatric Low-Grade Glioma (pLGG), the Most Common Form of Childhood Brain Tumor	Apr. 23	AQ
Day One Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Progress	Feb. 26	GL
Day One Announces Two New Appointments to Board of Directors	Jan. 17	GL
Day One to Present at the 42nd Annual J.P. Morgan Healthcare Conference	Dec. 19	GL
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine	Nov. 17	GL
Day One Announces Tovorafenib FIREFLY-1 Data Published in Nature Medicine	Nov. 17	AQ
Day One Biopharmaceuticals : Change in Certifying Accountants - Form 8-K	Nov. 15	PU
Day One to Participate in the Piper Sandler 35th Annual Healthcare Conference	Nov. 14	GL
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress	Nov. 06	GL
Day One Reports Third Quarter 2023 Financial Results and Corporate Progress	Nov. 06	AQ
Day One Biopharmaceuticals : Corporate Presentation - October 2023	23-10-30	PU
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	23-10-30	GL
Day One Announces FDA Acceptance of NDA and Priority Review for Tovorafenib in Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	23-10-30	AQ
Day One Announces Updated FIREFLY-1 Data for Tovorafenib and Completion of Rolling NDA Submission to FDA for Relapsed or Progressive Pediatric Low-Grade Glioma (pLGG)	23-09-11	GL
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience	23-08-16	GL
Sprint Bioscience licenses the VADA (VRK1) program to Day One Biopharmaceuticals	23-08-16	AQ
Day One Announces VRK1 License Agreement and Research Collaboration with Sprint Bioscience	23-08-16	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Press Releases Day One Biopharmaceuticals, Inc.

Equities

DAWN

US23954D1090

Press Releases

Filters